LDN Phase II Trial Results Published - Multiple Sclerosis Society
Main Category: Multiple SclerosisAlso Included In: Clinical Trials / Drug Trials; Neurology / Neuroscience
Article Date: 02 Mar 2010 - 3:00 PDT
email to a friend 
printer friendly 
opinions
| Patient / Public: |  |
3.2 (15 votes) |
| Healthcare Prof: |  |
|
| Article Opinions: | 2 posts |
Results of a phase II clinical trial on the safety and effectiveness of low dose naltrexone (LDN) as a symptom-relief treatment for people with MS have been published in the journal Annals of Neurology.
The results of the study suggest that LDN is safe and may have positive effects on the mental quality of life in people with MS; but no effect on a patient's physical quality of life.
The work, led by Dr. Bruce Cree at the University of California in San Francisco, is the first placebo controlled clinical trial to look at the effects of LDN in people with MS.
Researchers found vivid dreaming was the only symptom reported as a result of taking LDN but due to a high drop out rate among trial participants, concluded that larger scale trials are needed to determine the effect of LDN on overall quality of life.
Dr Susan Kohlhaas, Research Communications Officer at the MS Society said, "We are really pleased to see results of this study published. The next step will be to complete larger, more detailed clinical trials to determine the potential of LDN as a symptom relief therapy for people with MS."
Source
Multiple Sclerosis Society
Visit our multiple sclerosis section for the latest news on this subject.
MLA
11 Feb. 2012. <http://www.medicalnewstoday.com/releases/180804.php>
APA
http://www.medicalnewstoday.com/releases/180804.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Visitor Opinions In Chronological Order (2)
So It Increases...LDN Phase II Trial Results Published - Multiple Sclerosis Society
posted by John on 2 Mar 2010 at 11:32 am"may have positive effects on the mental quality of life in people with MS; but no effect on a patient's physical quality of life."
LDN is also a type of synthetic heroin that raises the person's Edorphin levels overnight, in turn, they wake up in the morning feeling somewhat charged up.
However, there is no effect on MS itself or the patient's physical quality of life. LDN doesn't stop or slow MS. It does nothing to alter the activity of the attacking cells that are destroying the patient's Myelin, thus disease progress will continue, but the patient will have a happy go lucky feeling in the morning, meanwhile the erosion of Myelin continues.
And of course, eventhough clinical trials are now being conducted, and the results are showing no modification or change to the progress of the disease, this still won't be good enough because the finding are not what they want to hear.
It's a false sense of security.
my experience with LDN
posted by Kevin G. on 5 Sep 2010 at 12:17 pmI have Primary Progressive Multiple Sclerosis, I started noticing problems in 2002. I was officially diagnosed in 2004. I was limping, among other problems, by 2005. I was on the traditional treatments for MS, and my symptoms progressed rapidly. I've been on LDN for a year and it has helped me in more ways than "a false sense of security." I noticed old symptoms . I never thought it would cure me, just help me with problems. And it did. I recently stopped taking LDN, and plan to start over again with my new regime in a month. My options are running out, as it's getting harder to walk with forearm-crutches. 8 years of of my body steadily deteriorating, LDN has been more than a sense of security. It's been 2 weeks since I stopped and my body, not my mind is suffering. LDN should be more accessible to everyone. I'll be in a wheelchair or moving a lot better by Christmas...stay tuned.
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Privacy Policy |
Terms and Conditions
MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
